<DOC>
	<DOC>NCT01375933</DOC>
	<brief_summary>The purpose of this study is to assess the comparability of the phase 3 lot and a single commercial lot of NicVAX in healthy smokers.</brief_summary>
	<brief_title>A Comparability Study of the Phase 3 Lot and a Single Commercial Lot of NicVAX in Healthy Adult Smokers</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male or female smokers, age 1855, who are currently smoking at least 10 cigarettes per day. Prior exposure to NicVAX or any other nicotine vaccine. History of clinically significant allergic reactions. Use of systemic steroids. Cancer or cancer treatment within 5 years. HIV infection. History of drug or alcohol abuse or dependence. Required treatment for depression within the past 12 months. Body mass index â‰¥ 30 [calculated as weight (kg)/height2 (m)]. Significant cardiovascular, hepatic, renal, psychiatric and/or respiratory disease. Inability to fulfill all visits for approximately 30 weeks.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Smoking</keyword>
	<keyword>NicVAX</keyword>
	<keyword>Smoking vaccine</keyword>
</DOC>